PE20171383A1 - Receptores de antigeno quimericos anti-dll3 y metodos de uso - Google Patents

Receptores de antigeno quimericos anti-dll3 y metodos de uso

Info

Publication number
PE20171383A1
PE20171383A1 PE2017001455A PE2017001455A PE20171383A1 PE 20171383 A1 PE20171383 A1 PE 20171383A1 PE 2017001455 A PE2017001455 A PE 2017001455A PE 2017001455 A PE2017001455 A PE 2017001455A PE 20171383 A1 PE20171383 A1 PE 20171383A1
Authority
PE
Peru
Prior art keywords
dll3
binding domain
chemerical
methods
antigen receptors
Prior art date
Application number
PE2017001455A
Other languages
English (en)
Inventor
Paul Anthony Escarpe
Scott J Dylla
David Liu
Robert A Stull
Original Assignee
Abbvie Stemcentrx Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Stemcentrx Llc filed Critical Abbvie Stemcentrx Llc
Publication of PE20171383A1 publication Critical patent/PE20171383A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2815—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3023—Lung
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Abstract

Se refiere a un receptor de antigeno quimerico que comprende un dominio de union anti-DLL3, que a su vez comprende un dominio de union anti-DLL3 scFv, donde dicho dominio de union anti-DLL3 scFv deriva de, comprende o compite por la union con un anticuerpo que comprende: i) una region variable de cadena liviana; y ii) una region variable de cadena pesada. Tambien se refiere a una composicion farmaceutica, a un vector de expresion, a una celula huesped y a un metodo de produccion. Dicho receptor de antigeno es util en el tratamiento de cancer de pulmon, melanoma, cancer de mama, entre otros
PE2017001455A 2015-02-23 2016-02-23 Receptores de antigeno quimericos anti-dll3 y metodos de uso PE20171383A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562119793P 2015-02-23 2015-02-23
US201562241662P 2015-10-14 2015-10-14
US201662296560P 2016-02-17 2016-02-17

Publications (1)

Publication Number Publication Date
PE20171383A1 true PE20171383A1 (es) 2017-09-15

Family

ID=56789774

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2017001455A PE20171383A1 (es) 2015-02-23 2016-02-23 Receptores de antigeno quimericos anti-dll3 y metodos de uso

Country Status (23)

Country Link
US (1) US20180044415A1 (es)
EP (1) EP3261650A4 (es)
JP (1) JP2018506981A (es)
KR (1) KR20170120158A (es)
CN (1) CN107405362A (es)
BR (1) BR112017017927A2 (es)
CA (1) CA2977502A1 (es)
CL (1) CL2017002150A1 (es)
CO (1) CO2017008804A2 (es)
CR (1) CR20170436A (es)
DO (1) DOP2017000199A (es)
EA (1) EA201791884A1 (es)
EC (1) ECSP17063327A (es)
HK (1) HK1249405A1 (es)
IL (1) IL254068A0 (es)
MA (1) MA41613A (es)
MX (1) MX2017010845A (es)
PE (1) PE20171383A1 (es)
PH (1) PH12017501521A1 (es)
SG (1) SG11201706804SA (es)
TW (1) TW201639887A (es)
WO (1) WO2016138038A1 (es)
ZA (1) ZA201705720B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11385233B2 (en) 2015-03-05 2022-07-12 Autolus Limited Methods of depleting malignant T-cells
US20230027993A1 (en) 2014-03-05 2023-01-26 Autolus Limited Methods
GB201403972D0 (en) 2014-03-06 2014-04-23 Ucl Business Plc Chimeric antigen receptor
CN108395482B (zh) * 2017-02-08 2021-02-05 西比曼生物科技（香港）有限公司 一种靶向cd20抗原嵌合抗原受体的构建及其工程化t细胞的活性鉴定
CN110944651A (zh) 2017-02-08 2020-03-31 蜻蜓疗法股份有限公司 用于自然杀伤细胞激活的多特异性结合蛋白及其治疗癌症的治疗性用途
CA3054079A1 (en) 2017-02-20 2018-08-23 Dragonfly Therapeutics, Inc. Proteins binding her2, nkg2d and cd16
JP2020530554A (ja) * 2017-07-20 2020-10-22 シートムエックス セラピューティクス，インコーポレイテッド 活性化抗体の特性を定性的および／または定量的に分析する方法およびその使用
KR102172092B1 (ko) 2017-09-19 2020-10-30 주식회사 엘지화학 열가소성 수지 조성물, 이의 제조방법 및 성형품
CR20200195A (es) 2017-10-13 2020-08-14 Harpoon Therapeutics Inc Proteínas de unión a antigenos de maduraciòn de celulas b
WO2019079009A1 (en) * 2017-10-20 2019-04-25 Nantbio, Inc. METHODS OF MONITORING IMMUNOTHERAPY OF BLADDER CANCER
PE20220278A1 (es) 2018-02-08 2022-02-25 Dragonfly Therapeutics Inc Dominios variables de anticuerpos que se dirigen al receptor nkg2d
US11110125B2 (en) * 2018-02-13 2021-09-07 Chimera Bioengineering, Inc. Coordinating gene expression using RNA destabilizing elements
US20220025037A1 (en) * 2018-04-03 2022-01-27 Dragonfly Therapeutics, Inc. Antibody variable domains targeting dll3, and use thereof
CA3095920A1 (en) * 2018-04-10 2019-10-17 Amgen Inc. Chimeric receptors to dll3 and methods of use thereof
AU2019267349A1 (en) * 2018-05-08 2020-10-29 Phanes Therapeutics, Inc. Anti-DLL3 antibodies and uses thereof
JP2022517301A (ja) * 2018-12-07 2022-03-08 カファ セラピューティクス リミテッド 腫瘍併用免疫療法
PE20220495A1 (es) * 2019-03-01 2022-04-07 Allogene Therapeutics Inc Receptores antigenicos quimericos y agentes de union dirigidos a dll3
CN113874526A (zh) * 2019-03-08 2021-12-31 肿瘤实验室诊断有限公司 癌症的诊断和预后
CA3132202A1 (en) * 2019-04-08 2020-10-15 Phanes Therapeutics, Inc. Humanized anti-dll3 chimeric antigen receptors and uses thereof
EP3999550A4 (en) * 2019-07-17 2023-09-06 Legend Biotech USA Inc. CHIMERIC ANTI-DLL3 ANTIGEN RECEPTORS AND USES THEREOF
CN114786686A (zh) * 2019-08-18 2022-07-22 嵌合体生物工程公司 Gold控制的转基因的联合疗法
WO2021155380A1 (en) * 2020-01-31 2021-08-05 Gensun Biopharma Inc. Bispecific t cell engagers
EP4313081A1 (en) * 2021-04-02 2024-02-07 Nanjing Legend Biotech Co., Ltd. Engineered immune cells and uses thereof
CN117169518B (zh) * 2023-11-03 2024-01-19 赛德特(北京)生物工程有限公司 T淋巴细胞制剂中的cd3抗体残留物的检测方法和试剂盒

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS62387B1 (sr) * 2010-01-29 2021-10-29 Chugai Pharmaceutical Co Ltd Anti-dll3 antitelo
CN106220739A (zh) * 2010-12-09 2016-12-14 宾夕法尼亚大学董事会 嵌合抗原受体‑修饰的t细胞治疗癌症的用途
EP3093293A1 (en) * 2012-02-24 2016-11-16 Stemcentrx, Inc. Anti dll3 antibodies and methods of use thereof
CN104661677A (zh) * 2012-06-22 2015-05-27 西托姆克斯治疗公司 抗Jagged 1/Jagged 2交叉反应抗体、可活化的抗Jagged抗体及其使用方法
GB201302447D0 (en) * 2013-02-12 2013-03-27 Oxford Biotherapeutics Ltd Therapeutic and diagnostic target
SI2958944T1 (sl) * 2013-02-22 2019-08-30 Abb Vie Stemcentrx Llc Konjugati protiDLL3-protitelo-PBD in njihove uporabe
WO2016179319A1 (en) * 2015-05-04 2016-11-10 Cellerant Therapeutics, Inc. Chimeric antigen receptors with ctla4 signal transduction domains

Also Published As

Publication number Publication date
EP3261650A4 (en) 2018-07-18
BR112017017927A2 (pt) 2018-04-10
JP2018506981A (ja) 2018-03-15
ECSP17063327A (es) 2017-10-31
EP3261650A1 (en) 2018-01-03
PH12017501521A1 (en) 2018-02-05
WO2016138038A1 (en) 2016-09-01
MA41613A (fr) 2018-01-02
SG11201706804SA (en) 2017-09-28
CR20170436A (es) 2018-01-29
IL254068A0 (en) 2017-10-31
US20180044415A1 (en) 2018-02-15
KR20170120158A (ko) 2017-10-30
MX2017010845A (es) 2017-12-11
EA201791884A1 (ru) 2018-03-30
CO2017008804A2 (es) 2018-01-31
DOP2017000199A (es) 2017-10-15
CL2017002150A1 (es) 2018-05-18
CA2977502A1 (en) 2016-09-01
HK1249405A1 (zh) 2018-11-02
CN107405362A (zh) 2017-11-28
TW201639887A (zh) 2016-11-16
ZA201705720B (en) 2020-02-26

Similar Documents

Publication Publication Date Title
PE20171383A1 (es) Receptores de antigeno quimericos anti-dll3 y metodos de uso
PE20210460A1 (es) Anticuerpos especificos para cd47 y pdl1
PH12017501039A1 (en) Antibodies targeting g-protein coupled receptor and methods of use
PE20170288A1 (es) Anticuerpos anti-lag3 y fragmentos de union a antigeno
PE20170772A1 (es) Anticuerpo monoclonal anti-ctla4 o su fragmento de union a antigeno, una composicion farmaceutica y uso
PE20170264A1 (es) Anticuerpos monoclonales contra el epitope de her2 y sus metodos de uso
PH12017502390A1 (en) Constructs targeting ny-eso-1 peptide/mhc complexes and uses thereof
CO2017005650A2 (es) Anticuerpos anti-interleucina-33
PH12018500380A1 (en) Anti-dll3 antibody drug conjugates and methods of use
PE20170286A1 (es) Diacuerpos heterodimericos biespecificos y sus usos
AR098465A1 (es) ANTICUERPOS ANTI-a-SINUCLEÍNA Y MÉTODOS DE UTILIZACIÓN
EA201792589A1 (ru) Антитела против cd123 и конъюгаты указанных антител
CR20180065A (es) Constructos de anticuerpo biespecíficos que se unen a egfrviii y cd3
PH12017500002A1 (en) Anti-cdh6 antibody drug conjugates
EA201592269A1 (ru) Способы и композиции для снижения иммуносупрессии опухолевыми клетками
AR090973A1 (es) Anticuerpos utiles para el diagnostico del cancer
PE20171060A1 (es) Receptores quimericos de antigeno anti-cldn y metodos de uso
PH12017500406A1 (en) Novel anti-mfi2 antibodies and methods of use
MA39896A (fr) Nouveaux anticorps antii-rnf43 et méthodes d'utilisation
WO2018119425A3 (en) Anti-lilrb3 antibodies and methods of use thereof
MX2023006786A (es) Anticuerpos inmunomoduladores biespecificos que se fijan a receptores coestimuladores y de puntos de control.
ES2721935T3 (es) Anticuerpos anti-BAG3 para uso terapéutico
MX2018007817A (es) Nuevos anticuerpos anti-mmp16 y metodos para su uso.
AR100270A1 (es) Anticuerpos ang2
MX2018013484A (es) Nuevos anticuerpos anti-tnfrsf21 y modos de uso.